NO20020574D0 - Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden - Google Patents
Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstandenInfo
- Publication number
- NO20020574D0 NO20020574D0 NO20020574A NO20020574A NO20020574D0 NO 20020574 D0 NO20020574 D0 NO 20020574D0 NO 20020574 A NO20020574 A NO 20020574A NO 20020574 A NO20020574 A NO 20020574A NO 20020574 D0 NO20020574 D0 NO 20020574D0
- Authority
- NO
- Norway
- Prior art keywords
- dihydropyrrole
- derivatives
- substituted
- act
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19936719A DE19936719A1 (de) | 1999-08-06 | 1999-08-06 | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
PCT/EP2000/007100 WO2001010833A1 (de) | 1999-08-06 | 2000-07-25 | Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20020574D0 true NO20020574D0 (no) | 2002-02-05 |
NO20020574L NO20020574L (no) | 2002-03-25 |
Family
ID=7917172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020574A NO20020574L (no) | 1999-08-06 | 2002-02-05 | Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden |
Country Status (25)
Country | Link |
---|---|
US (1) | US6642267B2 (no) |
EP (1) | EP1200402B1 (no) |
JP (1) | JP2003506437A (no) |
KR (1) | KR20020025214A (no) |
CN (1) | CN1378532A (no) |
AR (1) | AR028848A1 (no) |
AT (1) | ATE304530T1 (no) |
AU (1) | AU782435B2 (no) |
BR (1) | BR0013311A (no) |
CA (1) | CA2381033A1 (no) |
CO (1) | CO5200758A1 (no) |
CZ (1) | CZ2002441A3 (no) |
DE (2) | DE19936719A1 (no) |
ES (1) | ES2248104T3 (no) |
HK (1) | HK1046405A1 (no) |
HU (1) | HUP0201937A3 (no) |
IL (1) | IL147977A0 (no) |
MX (1) | MXPA02001212A (no) |
NO (1) | NO20020574L (no) |
NZ (1) | NZ516988A (no) |
PE (1) | PE20010402A1 (no) |
PL (1) | PL353854A1 (no) |
SK (1) | SK1702002A3 (no) |
WO (1) | WO2001010833A1 (no) |
ZA (1) | ZA200201788B (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1269482C (zh) * | 2001-05-18 | 2006-08-16 | 威克斯医药有限公司 | 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用 |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
AU2005322611A1 (en) * | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of Alzheimer's disease |
BRPI0520588B8 (pt) * | 2005-09-28 | 2021-05-25 | Auris Medical Ag | uso de composições farmacêuticas para o tratamento de doenças do ouvido interno |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
KR20090115951A (ko) | 2007-03-01 | 2009-11-10 | 프로비오드룩 아게 | 글루타미닐 사이클라제 저해제의 신규 용도 |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
NZ619895A (en) | 2008-08-12 | 2015-12-24 | Zinfandel Pharmaceuticals Inc | Method of identifying disease risk factors |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
CN102695546B (zh) | 2009-09-11 | 2014-09-10 | 前体生物药物股份公司 | 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物 |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
AU2012205798B2 (en) | 2011-01-10 | 2016-02-25 | Takeda Pharmaceutical Company Limited | Methods and drug products for treating Alzheimer's disease |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
KR102084185B1 (ko) | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
US10708389B2 (en) * | 2016-12-06 | 2020-07-07 | Intelligrated Headquarters, Llc | Phased deployment of scalable real time web applications for material handling system |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL258360A (no) * | 1960-11-25 | |||
GB2173499A (en) * | 1985-02-04 | 1986-10-15 | Ici Plc | Fungicidal dithiolopyrrolones |
GB2170498A (en) * | 1985-02-04 | 1986-08-06 | Ici Plc | Processes for making fungicidal dithiolopyrrolones |
GB9210393D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
-
1999
- 1999-08-06 DE DE19936719A patent/DE19936719A1/de not_active Ceased
-
2000
- 2000-07-25 IL IL14797700A patent/IL147977A0/xx unknown
- 2000-07-25 NZ NZ516988A patent/NZ516988A/en unknown
- 2000-07-25 DE DE50011178T patent/DE50011178D1/de not_active Expired - Lifetime
- 2000-07-25 HU HU0201937A patent/HUP0201937A3/hu unknown
- 2000-07-25 KR KR1020027001608A patent/KR20020025214A/ko not_active Application Discontinuation
- 2000-07-25 JP JP2001515300A patent/JP2003506437A/ja not_active Withdrawn
- 2000-07-25 PL PL00353854A patent/PL353854A1/xx not_active Application Discontinuation
- 2000-07-25 MX MXPA02001212A patent/MXPA02001212A/es active IP Right Grant
- 2000-07-25 CN CN00813944A patent/CN1378532A/zh active Pending
- 2000-07-25 EP EP00956273A patent/EP1200402B1/de not_active Expired - Lifetime
- 2000-07-25 CA CA002381033A patent/CA2381033A1/en not_active Abandoned
- 2000-07-25 WO PCT/EP2000/007100 patent/WO2001010833A1/de active IP Right Grant
- 2000-07-25 ES ES00956273T patent/ES2248104T3/es not_active Expired - Lifetime
- 2000-07-25 CZ CZ2002441A patent/CZ2002441A3/cs unknown
- 2000-07-25 SK SK170-2002A patent/SK1702002A3/sk not_active Application Discontinuation
- 2000-07-25 BR BR0013311-6A patent/BR0013311A/pt not_active IP Right Cessation
- 2000-07-25 AT AT00956273T patent/ATE304530T1/de active
- 2000-07-25 AU AU68279/00A patent/AU782435B2/en not_active Ceased
- 2000-07-31 AR ARP000103963A patent/AR028848A1/es not_active Application Discontinuation
- 2000-08-01 PE PE2000000761A patent/PE20010402A1/es not_active Application Discontinuation
- 2000-08-03 CO CO00058413A patent/CO5200758A1/es not_active Application Discontinuation
-
2002
- 2002-02-05 NO NO20020574A patent/NO20020574L/no not_active Application Discontinuation
- 2002-02-06 US US10/066,800 patent/US6642267B2/en not_active Expired - Fee Related
- 2002-03-04 ZA ZA200201788A patent/ZA200201788B/xx unknown
- 2002-10-28 HK HK02107776.3A patent/HK1046405A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN1378532A (zh) | 2002-11-06 |
CO5200758A1 (es) | 2002-09-27 |
NZ516988A (en) | 2004-11-26 |
ZA200201788B (en) | 2003-08-27 |
EP1200402A1 (de) | 2002-05-02 |
IL147977A0 (en) | 2002-09-12 |
SK1702002A3 (en) | 2002-07-02 |
HK1046405A1 (zh) | 2003-01-10 |
NO20020574L (no) | 2002-03-25 |
CA2381033A1 (en) | 2001-02-15 |
AU782435B2 (en) | 2005-07-28 |
KR20020025214A (ko) | 2002-04-03 |
HUP0201937A3 (en) | 2002-12-28 |
JP2003506437A (ja) | 2003-02-18 |
AR028848A1 (es) | 2003-05-28 |
ES2248104T3 (es) | 2006-03-16 |
CZ2002441A3 (cs) | 2002-05-15 |
HUP0201937A2 (en) | 2002-10-28 |
BR0013311A (pt) | 2003-01-28 |
ATE304530T1 (de) | 2005-09-15 |
DE19936719A1 (de) | 2001-02-15 |
AU6827900A (en) | 2001-03-05 |
MXPA02001212A (es) | 2002-07-02 |
WO2001010833A1 (de) | 2001-02-15 |
DE50011178D1 (de) | 2005-10-20 |
US20020161033A1 (en) | 2002-10-31 |
US6642267B2 (en) | 2003-11-04 |
PL353854A1 (en) | 2003-12-01 |
EP1200402B1 (de) | 2005-09-14 |
PE20010402A1 (es) | 2001-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20020574D0 (no) | Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden | |
NO20034122L (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
AP2004002982A0 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain. | |
NO20022925L (no) | EP4 reseptor selektive agonister for behandling av osteoporose | |
MXPA03009644A (es) | Grupos azabiciclicos sustituidos para el tratamiento de enfermedades. | |
NO20032360L (no) | EP4 reseptor selektive agonister for behandling av osteoporose | |
EE200100293A (et) | Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II | |
DK1208095T3 (da) | Dibenzopyraner som glucocorticoidreceptorantagonister til behandling af diabetes | |
DK1440059T3 (da) | 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister | |
NO20016246D0 (no) | Selektiv iGluR5 reseptorantagonist for behandling av migrene | |
DK1068202T3 (da) | 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister | |
HK1045684A1 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor. | |
DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
NO20000456L (no) | FremgangsmÕte for fremstilling av 1,2-dikloretan | |
NO20005386L (no) | Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom | |
DK1200402T3 (da) | Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande | |
ITMI992457A0 (it) | Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidrois ochinolin-3-carbossiammide | |
ITMI992459A0 (it) | Procedimento per la preparazione di marbofloxacina | |
DK1207159T3 (da) | Heteroaromatiske derivater som dopamin-D4-receptorantagonister | |
SI1200400T1 (en) | Substituted pyrrolidin-2,3,4-trion derivatives useful as nmda-receptor antagonists | |
NO20004422D0 (no) | FremgangsmÕte for fremstilling av sulfanyl-type endothelinreseptor-antagonister | |
ITMI20002173A0 (it) | Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-treraidroisochinolin-3-carbossiammide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |